secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0001576280-25-000245
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health Q2 revenue $232.1M (+31% YoY); raises FY2025 guidance to $915-925M
--------------------------------------------------------------------------------

- Q2 total revenue $232.1M (+31% YoY); Oncology $158.7M (+22%), Screening $14.8M, Biopharma $56.0M (+28%).
- Non-GAAP gross margin 66% (vs 60% YoY); net loss $99.9M ($0.80) vs $102.6M ($0.84) YoY.
- 2025 revenue guidance raised to $915-925M (24-25% growth) from prior $880-890M; non-GAAP gross margin guidance 63-64%.
- Shield screening test volume expected 68,000-73,000; Screening revenue guidance raised to $55-60M.
- Free cash flow burn -$65.9M in Q2 vs -$99.1M; core business ex-Screening on track for FCF breakeven in Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000157628025000245/0001576280-25-000245-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000157628025000245/gh-20250730.htm
  HTML page:      https://secwatch.observer/filing/0001576280-25-000245

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer